Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Adverse reactions to tattoos in the general population of Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Risk of skin cancer in HIV-infected patients: a Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Prevalence and risk of migraine in patients with rosacea: A population-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Adverse reactions to injectable soft tissue fillers

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Computational and cellular studies reveal structural destabilization and degradation of MLH1 variants in Lynch syndrome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Germline variants in oculocutaneous albinism genes and predisposition to familial cutaneous melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Global microRNA profiling of metastatic conjunctival melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • GenoMEL Study Group
Vis graf over relationer

BACKGROUND: Although rare in the general population, highly penetrant germline mutations in CDKN2A are responsible for 5%-40% of melanoma cases reported in melanoma-prone families. We sought to determine whether MELPREDICT was generalizable to a global series of families with melanoma and whether performance improvements can be achieved.

METHODS: In total, 2116 familial melanoma cases were ascertained by the international GenoMEL Consortium. We recapitulated the MELPREDICT model within our data (GenoMELPREDICT) to assess performance improvements by adding phenotypic risk factors and history of pancreatic cancer. We report areas under the curve (AUC) with 95% confidence intervals (CIs) along with net reclassification indices (NRIs) as performance metrics.

RESULTS: MELPREDICT performed well (AUC 0.752, 95% CI 0.730-0.775), and GenoMELPREDICT performance was similar (AUC 0.748, 95% CI 0.726-0.771). Adding a reported history of pancreatic cancer yielded discriminatory improvement (P < .0001) in GenoMELPREDICT (AUC 0.772, 95% CI 0.750-0.793, NRI 0.40). Including phenotypic risk factors did not improve performance.

CONCLUSION: The MELPREDICT model functioned well in a global data set of familial melanoma cases. Adding pancreatic cancer history improved model prediction. GenoMELPREDICT is a simple tool for predicting CDKN2A mutational status among melanoma patients from melanoma-prone families and can aid in directing these patients to receive genetic testing or cancer risk counseling.

OriginalsprogEngelsk
TidsskriftJournal of the American Academy of Dermatology
Vol/bind81
Udgave nummer2
Sider (fra-til)386-394
Antal sider9
ISSN0190-9622
DOI
StatusUdgivet - aug. 2019

Bibliografisk note

Copyright © 2019 American Academy of Dermatology, Inc. All rights reserved.

ID: 58278756